Evidence map›Paper›PMID 41353995›Full record

ArticleTranslational oncology2026

Phenazine 5,10-dioxide analogues as potential therapeutics in AML: Efficacy on patient-derived blasts, in zebrafish larvae xenografts and synergy with venetoclax.

Ingeborg Nerbø Reiten, Reidun Aesoy, Jan-Lukas Førde, Goraksha Machhindra Khose, Elvar Örn Viktorsson, Øystein Bruserud, Pål Rongved, Håkon Reikvam, Lars Herfindal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ingeborg Nerbø ReitenCentre for Pharmacy, Department of Clinical Science, University of Bergen, Norway.
Reidun AesoyCentre for Pharmacy, Department of Clinical Science, University of Bergen, Norway.
Jan-Lukas FørdeCentre for Pharmacy, Department of Clinical Science, University of Bergen, Norway.
Goraksha Machhindra KhoseSchool of Health Sciences, Faculty of Pharmaceutical Sciences, University of Iceland, Iceland.
Elvar Örn ViktorssonSchool of Health Sciences, Faculty of Pharmaceutical Sciences, University of Iceland, Iceland.
Øystein BruserudDepartment of Medicine Haukeland University Hospital, Bergen, Norway; K.G. Jebsen Center for Myeloid Malignancies, Department of Clinical Science, University of Bergen, Bergen, Norway.
Pål RongvedSchool of Pharmacy, Department of Pharmaceutical Chemistry, University of Oslo, Norway.
Håkon ReikvamDepartment of Medicine Haukeland University Hospital, Bergen, Norway; K.G. Jebsen Center for Myeloid Malignancies, Department of Clinical Science, University of Bergen, Bergen, Norway.
Lars HerfindalCentre for Pharmacy, Department of Clinical Science, University of Bergen, Norway. Electronic address: Lars.herfindal@uib.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although several new therapies against acute myeloid leukaemia (AML) have emerged the past years, patients who are ineligible for intensive chemotherapy are still treated with less effective treatments to minimise therapy-associated mortality. Several phenazine 5,10-dioxide derivates have previously demonstrated to selectively induce apoptosis in human AML cells. In the present work, we have continued investigations on phenazine 5,10-dioxides to reveal their therapeutic potential in AML using in vitro and in vivo experiments. From a panel of primary AML blasts from 61 non-selected patients, 58 showed high or intermediate response to treatment with the phenazine 5,10-dioxides. This included blasts with biological characteristics associated with poor prognosis, such as FLT3 internal tandem duplication, NPM-1 wild type, CD34

Indexed as

Acute myeloid leukemiaPatient blastsPhenazinesVenetoclax,Zebrafish larvae

Identifiers

PMID41353995
PMCPMC12741294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.